Scalper1 News
Drugmaker the Medicines Co. (MDCO) was suffering both on the stock market and in analyst opinion Thursday, a day after an FDA panel voted against approving its anti-platelet drug cangrelor. On Wednesday, trading on the firm’s shares were halted on the stock market after the panel voted 7-2 against approving the drug, which would be used to prevent clotting in patients undergoing cardiac stent procedures. The panel criticized the design of one of Scalper1 News
Scalper1 News